SCS adds to iPS portfolio
Wednesday, 08 October, 2008
Stem Cell Sciences [ASX: STC] has licensed technology developed at Cambridge University used to reprogram adult cells into stem cells.
The agreement relates specifically to patents for technology used to generate induced pluripotent stem (iPS) cells from mammalian cells.
The technology was developed by Professor Austin Smith. Smith, director of the Wellcome Trust Centre for Stem Cell Research.
Smith also serves as chairman of SCS's Scientific Advisory Board.
Overuse of inhalers can increase heart attack risk
Overuse of reliever inhalers is associated with higher risks of developing and dying from...
Unhealthy Western diet could accelerate cognitive decline
An unhealthy Western-style diet is associated with a faster cognitive decline in people with a...
Cancer drug enters clinical trials based on a false mechanism
A cancer drug currently being tested in patients appears to have entered clinical trials based on...
